Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $190.00

Becton, Dickinson and Company (NYSE:BDX) had its target price lifted by Royal Bank Of Canada from $180.00 to $190.00 in a research report sent to investors on Thursday, Marketbeat Ratings reports. Royal Bank Of Canada currently has a sector perform rating on the medical instruments supplier’s stock.

A number of other brokerages have also issued reports on BDX. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Barclays raised their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Trading Up 0.7%

Shares of BDX opened at $183.16 on Thursday. The stock has a fifty day moving average of $157.84 and a two-hundred day moving average of $161.70. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a market capitalization of $50.47 billion, a PE ratio of 55.17, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 11,779 shares of company stock valued at $1,974,669 in the last three months. Corporate insiders own 0.40% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently added to or reduced their stakes in BDX. Auto Owners Insurance Co raised its position in Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the period. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after buying an additional 4,223,149 shares during the period. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $3,721,533,000. State Street Corp raised its holdings in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after buying an additional 116,737 shares during the period. Finally, First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after buying an additional 1,651,592 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.